{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:33:11Z","timestamp":1790389991043,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.thromres.2011.11.034","type":"journal-article","created":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T20:15:35Z","timestamp":1325016935000},"page":"360-366","source":"Crossref","is-referenced-by-count":45,"title":["Hematologic malignancies and thrombosis"],"prefix":"10.1016","volume":"129","author":[{"given":"F.","family":"Elice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rodeghiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2011.11.034_bb0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2007-1002576","article-title":"Diagnosis and treatment of cancer-related thrombosis","volume":"18","author":"Scates","year":"1992","journal-title":"Semin Thromb Hemost"},{"issue":"1\u20132","key":"10.1016\/j.thromres.2011.11.034_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000046583","article-title":"Epidemiology of thrombosis in cancer","volume":"106","author":"Rickles","year":"2001","journal-title":"Acta Haematol"},{"issue":"1\u20132","key":"10.1016\/j.thromres.2011.11.034_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000046584","article-title":"Venous thromboembolism as first manifestation of cancer","volume":"106","author":"Piccioli","year":"2001","journal-title":"Acta Haematol"},{"issue":"1\u20132","key":"10.1016\/j.thromres.2011.11.034_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2004.07.016","article-title":"Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis","volume":"115","author":"Ziegler","year":"2005","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.034_bb0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6602945","article-title":"Increased risk of venous thromboembolism in patients with acute leukaemia","volume":"94","author":"Mohren","year":"2006","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.thromres.2011.11.034_bb0030","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"De Stefano","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"17","key":"10.1016\/j.thromres.2011.11.034_bb0035","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival","volume":"113","author":"Ku","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2011.11.034_bb0040","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0045","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2007.06677.x","article-title":"Thrombosis and acute lymphoblastic leukaemia","volume":"138","author":"Payne","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.034_bb0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1538-7836.2007.02383.x","article-title":"Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis","volume":"5","author":"Caruso","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2009.01.003","article-title":"Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment","volume":"22","author":"Nowak-G\u00f6ttl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000098700","article-title":"Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis","volume":"117","author":"Melillo","year":"2007","journal-title":"Acta Haematol"},{"issue":"10","key":"10.1016\/j.thromres.2011.11.034_bb0065","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.12948","article-title":"Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study","volume":"93","author":"Hunault-Berger","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.thromres.2011.11.034_bb0070","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood.V75.11.2112.2112","article-title":"Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients","volume":"75","author":"Rodeghiero","year":"1990","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2011.11.034_bb0075","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0049-3848(10)70013-X","article-title":"Open issues on bleeding and thrombosis in acute promyelocytic leukemia","volume":"125","author":"Sanz","year":"2010","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0080","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.V71.4.870.870","article-title":"A new procoagulant in acute leukemia","volume":"71","author":"Falanga","year":"1988","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2011.11.034_bb0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.1990.tb00394.x","article-title":"Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML)","volume":"44","author":"Scharf","year":"1990","journal-title":"Eur J Haematol"},{"issue":"4\u20135","key":"10.1016\/j.thromres.2011.11.034_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.thromres.2003.10.007","article-title":"Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/157016110791330799","article-title":"Thromboembolic complications in malignant haematological disorders","volume":"8","author":"Castelli","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"issue":"12","key":"10.1016\/j.thromres.2011.11.034_bb0100","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.thromres.2011.11.034_bb0105","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.thromres.2011.11.034_bb0110","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/sj.bjc.6602504","article-title":"Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis","volume":"92","author":"Mohren","year":"2005","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.034_bb0115","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0609.1995.tb00214.x","article-title":"Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance","volume":"54","author":"Ottinger","year":"1995","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.thromres.2011.11.034_bb0120","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/10428190600560991","article-title":"Venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"47","author":"Komrokji","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"s2","key":"10.1016\/j.thromres.2011.11.034_bb0125","first-page":"168","article-title":"Incidence of Venous Thromboembolism in Patients with Lymphoma","volume":"7","author":"Conlon","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.thromres.2011.11.034_bb0130","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.11623","article-title":"High incidence of thromboembolism in patients with central nervous system lymphoma","volume":"98","author":"Goldschmidt","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.thromres.2011.11.034_bb0135","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/annonc\/mdh385","article-title":"The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance","volume":"15","author":"Sallah","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.034_bb0140","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.thromres.2011.11.034_bb0145","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.thromres.2011.11.034_bb0150","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.034_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.thromres.2011.11.034_bb0160","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0165","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4065\/78.1.34","article-title":"Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.thromres.2011.11.034_bb0175","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bjc.6601579","article-title":"Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers","volume":"90","author":"Bartlett","year":"2004","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.thromres.2011.11.034_bb0180","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.thromres.2011.11.034_bb0185","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.thromres.2011.11.034_bb0190","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0195","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","article-title":"Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis","volume":"108","author":"Zonder","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2011.11.034_bb0200","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0205","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.034_bb0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7800-2-17","article-title":"Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis","volume":"2","author":"Srkalovic","year":"2005","journal-title":"Int Semin Surg Oncol"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CLM.2003.n.011","article-title":"Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival","volume":"4","author":"Zangari","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br J Haematol"},{"issue":"9200","key":"10.1016\/j.thromres.2011.11.034_bb0225","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(00)00019-2","article-title":"New insights into role of microenvironment in multiple myeloma","volume":"355","author":"Tricot","year":"2000","journal-title":"Lancet"},{"issue":"4\u20135","key":"10.1016\/j.thromres.2011.11.034_bb0230","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00001721-199010000-00013","article-title":"Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control","volume":"1","author":"Amrani","year":"1990","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0037-1614223","article-title":"Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6","volume":"79","author":"Stirling","year":"1998","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.034_bb0240","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1096-8652(199604)51:4<319::AID-AJH12>3.0.CO;2-9","article-title":"Acquired free protein S deficiency associated with multiple myeloma: a case report","volume":"51","author":"Deitcher","year":"1996","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.034_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0255","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(96)90116-X","article-title":"Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma","volume":"128","author":"Carr","year":"1996","journal-title":"J Lab Clin Med"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajh.10433","article-title":"Fibrinolytic activity in multiple myeloma","volume":"74","author":"Yagci","year":"2003","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajh.10449","article-title":"A non-immunological phospholipid-dependent coagulation inhibitor associated with IgGlambda-type multiple myeloma","volume":"75","author":"Takamiya","year":"2004","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.thromres.2011.11.034_bb0270","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MBC.0b013e3281067fb2","article-title":"Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients","volume":"18","author":"Zangari","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0275","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2009.23.0169","article-title":"Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone","volume":"28","author":"Zangari","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13506120500537285","article-title":"Natural history of thromboembolism in AL amyloidosis","volume":"13","author":"Halligan","year":"2006","journal-title":"Amyloid"},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2011.11.034_bb0285","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0049-3848(10)70027-X","article-title":"Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients","volume":"125","author":"Farge","year":"2010","journal-title":"Thromb Res"},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2011.11.034_bb0290","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/S0049-3848(10)70029-3","article-title":"Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines","volume":"125","author":"Lyman","year":"2010","journal-title":"Thromb Res"},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2011.11.034_bb0295","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0049-3848(10)70028-1","article-title":"Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management","volume":"125","author":"Mandal\u00e0","year":"2010","journal-title":"Thromb Res"},{"issue":"24","key":"10.1016\/j.thromres.2011.11.034_bb0300","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","article-title":"Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study","volume":"115","author":"Mitchell","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2011.11.034_bb0305","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.thromres.2011.11.034_bb0310","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.thromres.2011.11.034_bb0315","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.thromres.2011.11.034_bb0320","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","article-title":"Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy","volume":"18","author":"Minnema","year":"2004","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.thromres.2011.11.034_bb0325","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0330","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1378\/chest.06-2360","article-title":"Risk of thrombosis with lenalidomide and its prevention with aspirin","volume":"131","author":"Hirsh","year":"2007","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.thromres.2011.11.034_bb0335","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2011.11.034_bb0340","article-title":"Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide","author":"Larocca","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.034_bb0345","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.034_bb0350","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.thromres.2011.11.034_bb0355","first-page":"442","article-title":"Prevalence and patterns of symptomatic thromboembolism in oncohematology","volume":"83","author":"Sgarabotto","year":"1998","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.034_bb0360","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2011.11.034_bb0365","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.034_bb0370","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2005.05848.x","article-title":"Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma","volume":"132","author":"Hassoun","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.thromres.2011.11.034_bb0375","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","article-title":"Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma","volume":"5","author":"Palumbo","year":"2004","journal-title":"Hematol J"},{"issue":"5","key":"10.1016\/j.thromres.2011.11.034_bb0380","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"issue":"9594","key":"10.1016\/j.thromres.2011.11.034_bb0385","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9513","key":"10.1016\/j.thromres.2011.11.034_bb0390","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.034_bb0395","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481100630X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481100630X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T11:47:50Z","timestamp":1593431270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938481100630X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S004938481100630X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2011.11.034","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}